Decreased levels of PC1/3, PC2 and SgIII have very recently been found in large-scale proteomic CSF screens from AD patients, but this has not been immunologically verified yet [24, 70–74], whereas variable results for CysC, CPE and SgII have been obtained [24, 71, 75–78]. This evidence concerns the gene SCG2 and Alzheimer disease.